My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Virpax Pharmaceuticals, Inc. - Common Stock (NQ:VRPX)

0.6695 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Virpax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Virpax Pharmaceuticals Announces Leadership Transition

November 17, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

November 15, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review

October 31, 2023

From Virpax Pharmaceuticals

Via Business Wire

Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research

October 12, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals

October 02, 2023

From Virpax Pharmaceuticals

Via Business Wire

Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies

September 27, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI

September 26, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses

September 21, 2023

From Altasciences

Via Business Wire

Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals

September 18, 2023

From Virpax Pharmaceuticals

Via Business Wire

Virpax Pharmaceuticals Updates on Litigation

September 05, 2023

From Virpax Pharmaceuticals

Via Business Wire

Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference

August 28, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments

August 14, 2023

From Virpax® Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method

August 10, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023

July 24, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery

July 13, 2023

From Virpax Pharmaceuticals

Via Business Wire

Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council

June 21, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals Announces CFO Transition

June 20, 2023

From Virpax Pharmaceuticals

Via Business Wire

Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

June 13, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments

May 12, 2023

From Virpax® Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar

May 10, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023

May 04, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™

April 27, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Reports on Progress of Envelta™

April 05, 2023

From Virpax Pharmaceuticals

Via Business Wire

Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors

March 28, 2023

From Virpax Pharmaceuticals

Via Business Wire

Virpax Pharmaceuticals Reports 2022 Year-End Results

March 22, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)

February 13, 2023

From Virpax Pharmaceuticals

Via Business Wire

Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China

January 31, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™

January 18, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts

January 10, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)

January 04, 2023

From Virpax Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.